Acrux (ASX:ACR) Short-Term Debt: A$0.76 Mil (As of Dec. 2025)


What is Acrux Short-Term Debt?

Acrux ASX:ACR Short-Term Debt is A$0.76 Mil as of Dec. 2025. The stock has 6 warning signs investors should review.

Acrux's Short-Term Debt for the quarter that ended in Dec. 2025 was A$0.76 Mil.

Acrux's quarterly Short-Term Debt increased from Dec. 2024 (A$0.30 Mil) to Jun. 2025 (A$1.73 Mil) but then declined from Jun. 2025 (A$1.73 Mil) to Dec. 2025 (A$0.76 Mil).

Acrux's annual Short-Term Debt increased from Jun. 2023 (A$0.00 Mil) to Jun. 2024 (A$1.49 Mil) and increased from Jun. 2024 (A$1.49 Mil) to Jun. 2025 (A$1.73 Mil).

Acrux Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Acrux Short-Term Debt Related Terms

Acrux Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Acrux's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acrux Short-Term Debt Chart

Acrux Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 1.49 1.73

Acrux Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.31 1.49 0.30 1.73 0.76
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of A$0.76 Mil mean?
Acrux (ASX:ACR) has a Short-Term Debt of A$0.76 Mil as of Dec. 2025.
Is Acrux's Short-Term Debt too high?
Acrux's current Short-Term Debt is A$0.76 Mil.
How does Acrux's Short-Term Debt compare to VRTX and REGN?
Acrux's Short-Term Debt of A$0.76 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Acrux's current Short-Term Debt is A$0.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acrux stock overvalued right now?
Based on GuruFocus' analysis, Acrux (ASX:ACR) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.03, compared to a current price of A$0.01 — trading 61.7% below its estimated fair value. The current Short-Term Debt is A$0.76 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Acrux (ASX:ACR), the current Short-Term Debt is A$0.76 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Acrux Business Description

Other Exchanges ARUXF:USAFJY:Germany
Address 103-113 Stanley Street, West Melbourne, Melbourne, VIC, AUS, 3003
Acrux Ltd is a dynamic Australian drug delivery specialist with expertise in developing and commercialising patient-preferred healthcare products for world-wide markets. Its talent creates value through the development and commercialisation of healthcare products using owned or acquired technologies. The group's products are patient preferred, protected by patent or other means, and use creative drug delivery.